December 7, 2010

Terry Van Dyke, PhD
Director, Mouse Genetics Program, The National Cancer Institute

Cancer Basic and Translation to the Clinic: What Engineered Mice are Teaching Us

Needs: Technology is available to develop better pre-clinical systems to predict efficacy and develop hypotheses for human research design. Currently, preclinical space in drug development results in only 5% approval to subsequent clinical trials, with most failures due to lack of efficacy.

Objectives: To understand current preclinical model systems for cancer; to understand the relevant issues in designing effective preclinical assessment based on current human disease knowledge; and to obtain an appreciation of the complexity of cancer development in vivo.